Hyphens Pharma International Ltd
SGX:1J5
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.26
0.39
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SGD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Hyphens Pharma International Ltd
Revenue
Hyphens Pharma International Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Revenue
S$185.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Revenue
$109.2m
|
CAGR 3-Years
197%
|
CAGR 5-Years
53%
|
CAGR 10-Years
92%
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Revenue
S$253m
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Revenue
S$7.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Hyphens Pharma International Ltd
Glance View
Hyphens Pharma International Ltd. is an investment holding company, which engages in the provision of specialty pharmaceutical and consumer healthcare products. The firm's principal activities are those of an investment holding company and provision of management services. The firm's segments include specialty pharma principals, proprietary brands, and medical hypermart and digital. The specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position itself as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.
See Also
What is Hyphens Pharma International Ltd's Revenue?
Revenue
185.3m
SGD
Based on the financial report for Jun 30, 2025, Hyphens Pharma International Ltd's Revenue amounts to 185.3m SGD.
What is Hyphens Pharma International Ltd's Revenue growth rate?
Revenue CAGR 5Y
8%
Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for Hyphens Pharma International Ltd have been 9% over the past three years , 8% over the past five years .